Ex Vivo Gene Therapy for Epidermolysis Bullosa

Doctor Emily Gorel presents an overview of ex vivo gene therapy for epidermolysis bullosa (EB), focusing on corrected keratinocyte grafts. She highlights the severe impact of EB on patients' lives, including chronic wounds and the need for multidisciplinary care. The presentation emphasizes the exciting advancements in EB research, noting that 2023 marked a significant year with multiple FDA approvals for EB treatments. The process of ex vivo gene therapy involves harvesting patients' keratinocytes, correcting genetic defects, and grafting them back, with promising long-term results. Gorel discusses the PZ Cell treatment, detailing the phase 1 and phase 3 studies showing substantial wound healing and pain reduction among treated patients compared to controls. Safety data from trials indicate manageable side effects, mainly procedural pain and infections, with no severe adverse events linked to the therapy. Other emerging techniques include gene editing with CRISPR and novel fibroblast therapies, alongside the use of mesenchymal stem cells for EB management. Gorel concludes with reflections on the progress made in EB treatments and expresses gratitude to the patients and research teams involved.